Skip to main content
. 2016 Apr 20;2016(4):CD008541. doi: 10.1002/14651858.CD008541.pub3

Silberstein 2008 Study 2.

Study characteristics
Methods Multicentre, R, DB, PC, parallel group. Single dose to treat single attack
Medication taken when PI mild and within 1 h of onset
Assessments at 0, 0.5, 1, 2, 4, 24 h
Participants Migraine ± aura (IHS 2004), aged 18 to 65 years. History: ≥ 6 months with frequency of 2 to 6 attacks per month, and ≤ 15 per month. Untreated severity ≥ moderate, with identifiable mild pain phase
Excluded: uncontrolled hypertension, cardio‐ or cerebrovascular disease, gastrointestinal history
N = 542 (535 for efficacy)
F = 90.5%
Mean age 41 years
66% without aura
Interventions Sumatriptan 85 mg plus naproxen 500 mg, n = 278
Placebo, n = 264
Rescue medication allowed after 2 h if necessary (not triptans, NSAID‐containing, ergot‐containing or ergot‐like medication)
Outcomes Pain‐free at 2 h
24‐h sustained pain‐free
Presence and relief of associated symptoms at 2 h
Presence and relief of functional disability at 2 h (from Taylor 2007)
Use of rescue medication
AEs
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk "Computer‐generated randomization schedule"
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection bias)
All outcomes Low risk "Matching placebo"
Incomplete outcome data (attrition bias)
All outcomes Low risk Drop‐outs described
Study size Low risk > 200 participants per treatment arm